Biblio
Found 118 results
Filters: Keyword is Humans [Clear All Filters]
Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues.. Bioorg Med Chem Lett. 22(2):1023-6.
.
2012. Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer's disease.. Adv Pharmacol. 64:327-71.
.
2012. Intranasal delivery of biologics to the central nervous system.. Adv Drug Deliv Rev. 64(7):614-28.
.
2012. The matrix protein CCN1/CYR61 is required for α(V)β5-mediated cancer cell migration.. Cell Biochem Funct. 30(8):687-95.
.
2012. Minireview: translational animal models of human menopause: challenges and emerging opportunities.. Endocrinology. 153(8):3571-8.
.
2012. Development of potent μ and δ opioid agonists with high lipophilicity.. J Med Chem. 54(1):382-6.
.
2011. Discovery of a potent and efficacious peptide derivative for δ/μ opioid agonist/neurokinin 1 antagonist activity with a 2',6'-dimethyl-L-tyrosine: in vitro, in vivo, and NMR-based structural studies.. J Med Chem. 54(7):2029-38.
.
2011. Estrogen receptor β-selective phytoestrogenic formulation prevents physical and neurological changes in a preclinical model of human menopause.. Menopause. 18(10):1131-42.
.
2011. The role of soy isoflavones in menopausal health: report of The North American Menopause Society/Wulf H. Utian Translational Science Symposium in Chicago, IL (October 2010).. Menopause. 18(7):732-53.
.
2011. Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions.. Mol Aspects Med. 32(4-6):247-57.
.
2011. Synthesis and biological evaluation of new opioid agonist and neurokinin-1 antagonist bivalent ligands.. Bioorg Med Chem. 19(20):6135-42.
.
2011. Targeting mitochondrial bioenergetics for Alzheimer's prevention and treatment.. Curr Pharm Des. 17(31):3474-9.
.
2011. Menopause and mitochondria: windows into estrogen effects on Alzheimer's disease risk and therapy.. Prog Brain Res. 182:77-96.
.
2010. Recently patented and promising ORL-1 ligands: where have we been and where are we going? Expert Opin Ther Pat. 20(3):291-305.
.
2010. Estrogen-induced plasticity from cells to circuits: predictions for cognitive function.. Trends Pharmacol Sci. 30(4):212-22.
.
2009. Expression of bile acid transporting proteins in Barrett's esophagus and esophageal adenocarcinoma.. Am J Gastroenterol. 104(2):302-9.
.
2009. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease.. Proc Natl Acad Sci U S A. 106(34):14670-5.
.
2009. Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells.. Neoplasia. 10(5):450-61.
.
2008. Estradiol-17beta-induced human neural progenitor cell proliferation is mediated by an estrogen receptor beta-phosphorylated extracellularly regulated kinase pathway.. Endocrinology. 149(1):208-18.
.
2008. Estrogen regulation of glucose metabolism and mitochondrial function: therapeutic implications for prevention of Alzheimer's disease.. Adv Drug Deliv Rev. 60(13-14):1504-11.
.
2008. The healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications.. Trends Neurosci. 31(10):529-37.
.
2008. Progesterone receptors: form and function in brain.. Front Neuroendocrinol. 29(2):313-39.
.
2008. Regenerative potential of allopregnanolone.. Brain Res Rev. 57(2):398-409.
.
2008. The role of COX-2 in heart pathology.. Cardiovasc Hematol Agents Med Chem. 6(1):69-79.
.
2008. Identification of Fn14/TWEAK receptor as a potential therapeutic target in esophageal adenocarcinoma.. Int J Cancer. 121(10):2132-9.
.
2007.